DE69033631T2 - Therapeutische verwendungen der hypervariablen region des monoklonalen antikörpers m195 und konstrukte davon - Google Patents
Therapeutische verwendungen der hypervariablen region des monoklonalen antikörpers m195 und konstrukte davonInfo
- Publication number
- DE69033631T2 DE69033631T2 DE69033631T DE69033631T DE69033631T2 DE 69033631 T2 DE69033631 T2 DE 69033631T2 DE 69033631 T DE69033631 T DE 69033631T DE 69033631 T DE69033631 T DE 69033631T DE 69033631 T2 DE69033631 T2 DE 69033631T2
- Authority
- DE
- Germany
- Prior art keywords
- monoclonal antibody
- hypervariable region
- constructs
- therapeutic use
- radioisotope
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 108091007491 NSP3 Papain-like protease domains Proteins 0.000 title abstract 2
- 230000001225 therapeutic effect Effects 0.000 title 1
- 206010000830 Acute leukaemia Diseases 0.000 abstract 1
- 230000001154 acute effect Effects 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 208000024207 chronic leukemia Diseases 0.000 abstract 1
- 229940127089 cytotoxic agent Drugs 0.000 abstract 1
- 239000002254 cytotoxic agent Substances 0.000 abstract 1
- 231100000599 cytotoxic agent Toxicity 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6817—Toxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
- A61K51/1069—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from blood cells, e.g. the cancer being a myeloma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3061—Blood cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Optics & Photonics (AREA)
- Genetics & Genomics (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Hematology (AREA)
- Toxicology (AREA)
- Biotechnology (AREA)
- Oncology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US45091889A | 1989-12-14 | 1989-12-14 | |
PCT/US1990/007436 WO1991009058A1 (en) | 1989-12-14 | 1990-12-14 | Therapeutic uses of the hypervariable region of monoclonal antibody m195 and constructs thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
DE69033631D1 DE69033631D1 (de) | 2000-10-26 |
DE69033631T2 true DE69033631T2 (de) | 2001-05-17 |
Family
ID=23790050
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE69033631T Expired - Lifetime DE69033631T2 (de) | 1989-12-14 | 1990-12-14 | Therapeutische verwendungen der hypervariablen region des monoklonalen antikörpers m195 und konstrukte davon |
Country Status (9)
Country | Link |
---|---|
US (1) | US5730982A (de) |
EP (1) | EP0504327B1 (de) |
JP (1) | JPH05503632A (de) |
AT (1) | ATE196477T1 (de) |
AU (1) | AU659083B2 (de) |
CA (1) | CA2072017A1 (de) |
DE (1) | DE69033631T2 (de) |
ES (1) | ES2152216T3 (de) |
WO (1) | WO1991009058A1 (de) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5776093A (en) | 1985-07-05 | 1998-07-07 | Immunomedics, Inc. | Method for imaging and treating organs and tissues |
US5714350A (en) | 1992-03-09 | 1998-02-03 | Protein Design Labs, Inc. | Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region |
ZA932523B (en) * | 1992-04-10 | 1994-10-08 | Res Dev Foundation | Immunotoxins directed against cd33 related surface antigens |
US6599505B1 (en) | 1992-04-10 | 2003-07-29 | Research Development Foundation | Immunotoxins directed against CD33 related surface antigens |
WO1994007138A1 (en) | 1992-09-14 | 1994-03-31 | Fodstad Oystein | Detection of specific target cells in specialized or mixed cell population and solutions containing mixed cell populations |
NO180658C (no) | 1994-03-10 | 1997-05-21 | Oeystein Fodstad | Fremgangsmåte og anordning for deteksjon av spesifikke målceller i spesialiserte eller blandede cellepopulasjoner og opplösninger som inneholder blandede cellepopulasjoner |
NO961031D0 (no) * | 1996-03-13 | 1996-03-13 | Det Norske Radiumshospital Tum | Fremgangsmåte til å drepe uönskede målceller |
US20060073133A1 (en) * | 1997-04-02 | 2006-04-06 | Kikly Kristine K | Sialoadhesin factor-3 antibodies |
US7361336B1 (en) * | 1997-09-18 | 2008-04-22 | Ivan Bergstein | Methods of cancer therapy targeted against a cancer stem line |
ES2299256T3 (es) * | 1998-05-26 | 2008-05-16 | Sloan-Kettering Institute For Cancer Research | Constructos que emiten particulas alfa y sus usos. |
US7736651B1 (en) | 2000-11-24 | 2010-06-15 | Sloan-Kettering Institute For Cancer Research | Alpha emitting constructs and uses thereof |
IT1307826B1 (it) * | 1999-12-16 | 2001-11-19 | Dipartimento Di Medicina Speri | Metodo diagnostico per il riconoscimento di cellule mieloidi normali eleucemiche, ligandi utilizzati in detto metodo e formulazioni ad uso |
ZA200503075B (en) * | 2002-11-07 | 2006-09-27 | Immunogen Inc | Anti-CD33 antibodies and method for treatment of acute myeloid leukemia using the same |
WO2008030538A2 (en) * | 2006-09-07 | 2008-03-13 | Stemline Therapeutics, Inc. | Cancer stem cell-targeted cancer therapy |
AU2007317333A1 (en) * | 2006-11-02 | 2008-05-15 | Seattle Genetics, Inc. | Methods of treating neoplastic, autoimmune and inflammatory diseases |
DE102009045006A1 (de) * | 2009-09-25 | 2011-04-14 | Technische Universität Dresden | Anti-CD33 Antikörper und ihre Anwendung zum Immunotargeting bei der Behandlung von CD33-assoziierten Erkrankungen |
CN107922480B (zh) | 2015-06-12 | 2022-09-23 | 艾利妥 | 抗cd33抗体及其使用方法 |
EP3307779A2 (de) | 2015-06-12 | 2018-04-18 | Alector LLC | Anti-cd33-antikörper und verfahren zur verwendung davon |
CN117700548A (zh) | 2017-08-03 | 2024-03-15 | 艾利妥 | 抗cd33抗体及其使用方法 |
US20200276339A1 (en) * | 2017-12-04 | 2020-09-03 | Actinium Pharmaceuticals, Inc. | Methods for treatment of patients with myelodysplastic syndromes |
EA202190235A1 (ru) | 2018-08-31 | 2021-07-02 | Алектор Ллс | Антитела к cd33 и способы их применения |
US11666672B2 (en) | 2018-11-21 | 2023-06-06 | City Of Hope | Anti-CD33 antibody-guided imaging and treatment of acute myeloid leukemia |
WO2023081898A1 (en) | 2021-11-08 | 2023-05-11 | Alector Llc | Soluble cd33 as a biomarker for anti-cd33 efficacy |
-
1990
- 1990-12-14 DE DE69033631T patent/DE69033631T2/de not_active Expired - Lifetime
- 1990-12-14 EP EP91904912A patent/EP0504327B1/de not_active Expired - Lifetime
- 1990-12-14 WO PCT/US1990/007436 patent/WO1991009058A1/en active IP Right Grant
- 1990-12-14 AT AT91904912T patent/ATE196477T1/de not_active IP Right Cessation
- 1990-12-14 JP JP91504637A patent/JPH05503632A/ja active Pending
- 1990-12-14 AU AU73135/91A patent/AU659083B2/en not_active Expired
- 1990-12-14 ES ES91904912T patent/ES2152216T3/es not_active Expired - Lifetime
- 1990-12-14 CA CA002072017A patent/CA2072017A1/en not_active Abandoned
-
1995
- 1995-02-02 US US08/383,615 patent/US5730982A/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
EP0504327A4 (en) | 1993-06-30 |
CA2072017A1 (en) | 1991-06-15 |
EP0504327B1 (de) | 2000-09-20 |
EP0504327A1 (de) | 1992-09-23 |
WO1991009058A1 (en) | 1991-06-27 |
AU659083B2 (en) | 1995-05-11 |
AU7313591A (en) | 1991-07-18 |
ATE196477T1 (de) | 2000-10-15 |
ES2152216T3 (es) | 2001-02-01 |
JPH05503632A (ja) | 1993-06-17 |
DE69033631D1 (de) | 2000-10-26 |
US5730982A (en) | 1998-03-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69033631D1 (de) | Therapeutische verwendungen der hypervariablen region des monoklonalen antikörpers m195 und konstrukte davon | |
EP0331034A3 (en) | Functionally specific antibodies | |
ATE46084T1 (de) | Immunotoxin-konjugate. | |
EP0458079A3 (en) | Ultrasonic contrast agent, its preparation and application as diagnostic or therapeutic | |
ATE267610T1 (de) | Glykosylierte igg antikörper | |
DE69429095D1 (de) | Humanisierte antikoerper | |
CA2195557A1 (en) | Immunoconjugates and humanized antibodies specific for b-cell lymphoma and leukemia cells | |
LU91271I2 (fr) | Natalizumab et ses dérivés pharmaceutiquement acceptables (TYSABRI) | |
DE68929384D1 (de) | Therapeutische Zusammensetzungen die monoklonale Antikörper enthalten gegen den menschlichen Rezeptor für epidermalen Wachstumsfaktor | |
NO910923L (no) | Trifunksjonell antistofflignende forbindelse som et kombinert diagnostisk og terapeutisk middel. | |
IL87885A0 (en) | Compounds having antiprogestational and anti-estrogenic activities for the treatment of tumours | |
DE68912334T2 (de) | Immunokonjugate für krebs-diagnose und -therapie. | |
EP0141079A3 (en) | Monoclonal antibodies specific for membrane-associated antigens | |
GB9009106D0 (en) | Processes and intermediates for synthetic antibody derivatives | |
OA04205A (fr) | L'exclusion (anti-aliasing) des fréquences spatiales au moyen du placement de geophones et de sources. | |
IT7927258A0 (it) | Procedimento di deposizione chimica di oro per riduzione autocatalitica. | |
IT8024223A0 (it) | Procedimento di valorizzazione difrazioni c4 olefiniche. | |
IT8719292A0 (it) | Composizione di anticorpi monoclonali umani cross-protettivi. | |
FI924605A0 (fi) | Antikroppkonjugater foer behandling av neoplastiska sjukdomar | |
FI853389A0 (fi) | Tumoerlaekemedel och foerfarande foer dess framstaellning. | |
DE3485965T2 (de) | Monoklonaler antikoerper mit spezifitaet gegen nur einen typ eines isozyms der schweren kette des menschlichen herzmyosins. | |
DE69527868D1 (de) | Monoklonaler Antikörper gegen den tumorzytotoxischen Faktor II (TCF-II) | |
EP0622082A4 (de) | Immunkomplex. | |
FI953708A0 (fi) | Menetelmä terapeuttisesti aktiivisten makrosyklisten bifunktionaalisten kelaatinmuodostajien, niiden kompleksien sekä niiden vasta-ainekonjugaattien valmistamiseksi | |
NO862346D0 (no) | Fremgangmsaate og maskin for tilsetting av farvemidler til malinger og fernisser. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition |